Connor, Clark & Lunn Investment Management (CC&L)
SLXP

Connor, Clark & Lunn Investment Management (CC&L)’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21,000
Closed -$3.28M – 694
2014
Q3 		$3.28M Buy
21,000
+17,400
+483% +$2.52M 0.03% 179
2014
Q2 		$473K Sell
3,600
-9,300
-72% -$1.03M ﹤0.01% 395
2014
Q1 		$1.48M Buy
+12,900
New +$1.32M 0.01% 319

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SLXP Position: Q4 2014 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 21,000 shares — an estimated $3.28M sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SLXP in Q1 2014 and held it in 3 quarters. The position peaked at $3.28M in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 21,000 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $3.28M.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q1 2014 and held it in 3 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s SALIX PHARMACEUTICALS LTD DEL position peaked at $3.28M in Q3 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2014, filed 12 Feb 2015.